Breaking News Instant updates and real-time market news.

COST

Costco

$157.09

-9.98 (-5.97%)

, AMZN

Amazon.com

$989.58

8.73 (0.89%)

16:21
10/06/17
10/06
16:21
10/06/17
16:21

On The Fly: Top stock stories for Friday

Stocks began the session in negative territory and largely remained there for most of the session, with only the Nasdaq closing in higher territory. The market's most recent rally has put together six consecutive all-time closing highs; the first time that has happened since the late 1990's. The market was hit with an early headwind with the lower than expected monthly Non-Farm Payrolls report which was significantly impacted by Hurricane Harvey and Irma. Despite the disappointment, the averages remained close to the flat line and moved within a very narrow range. Oil prices were weak and closed down roughly 2.8% just a week after notching a five-month high. ECONOMIC EVENTS: In the U.S., analysts had been expecting job growth to slump in September due to Hurricanes Harvey and Irma, but still predicted a net addition of jobs. However, the economy lost 33,000 jobs last month, marking the first decline since September 2010. The unemployment rate declined slightly to 4.2% and average hourly wages rose 2.9% from a year ago. Wholesale sales jumped 1.7% in August with inventories up 0.9%. In energy news, Baker Hughes reported that the U.S. rig count is down 4 rigs from last week to 936. COMPANY NEWS: Shares of Costco (COST) slid roughly 6% and the stock was downgraded to Equal Weight from Overweight at Morgan Stanley despite the company's report last night of better than expected Q4 earnings. Analyst Simeon Gutman, who penned the downgrade, and his peer at Deutsche Bank, Paul Trussell, both voiced concerns about its membership growth... Meanwhile, Amazon (AMZN) shares were nearly 1% higher after CNBC reported that the company is close to a decision over whether to enter the drug sales market. According to the report, which cites an email from Amazon as well as a source familiar with the situation, the company will decide before Thanksgiving whether it will opt to sell prescription drugs online. MAJOR MOVERS: Among the notable gainers was Synchronoss (SNCR), which jumped 32% after entering into an exclusivity agreement with Siris Capital to allow for negotiation of definitive agreements, including a potential sale of the company's Intralinks unit. Also higher was Ferroglobe (GSM), which gained 9.2% after Oppenheimer analyst Ian Zaffino said he views the Department of Commerce's preliminary silicon metal anti-dumping ruling as highly favorable for the company. Albemarle (ALB) was among the noteworthy losers, dropping 1.8% after Goldman Sachs analyst Robert Koort downgraded the stock to Neutral and removed the shares from his firm's Conviction Buy list. Also lower was Darling Ingredients (DAR), which fell 8.4% after JPMorgan analyst Thomas Palmer downgraded the stock to Neutral citing valuation as well as regulatory risk. INDEXES: The Dow fell 1.72, or 0.01%, to 22,773.67, the Nasdaq gained 4.82, or 0.07%, to 6,590.18, and the S&P 500 declined 2.74, or 0.11%, to 2,549.33.

COST

Costco

$157.09

-9.98 (-5.97%)

AMZN

Amazon.com

$989.58

8.73 (0.89%)

SNCR

Synchronoss

$14.15

3.43 (32.00%)

GSM

Ferroglobe

$14.76

1.24 (9.17%)

ALB

Albemarle

$137.19

-2.47 (-1.77%)

DAR

Darling Ingredients

$16.38

-1.51 (-8.44%)

  • 08

    Oct

  • 17

    Oct

  • 19

    Oct

  • 22

    Oct

  • 09

    Nov

  • 14

    Nov

  • 15

    Nov

COST Costco
$157.09

-9.98 (-5.97%)

10/06/17
BARD
10/06/17
NO CHANGE
Target $200
BARD
Outperform
Any post-earnings pullback in Costco provides a buying opportunity, says Baird
Baird analyst Peter Benedict noted Costco reported better than expected Q4 earnings and said it remains a compelling growth staple idea with its healthy fundamentals and an improved valuation profile. The analyst said any pullback in Costco share would be a good buying opportunity and shares look attractive at current levels. Benedict reiterated his Outperform rating and $200 price target on Costco shares.
10/06/17
MSCO
10/06/17
DOWNGRADE
MSCO
Equal Weight
Costco downgraded to Equal Weight from Overweight at Morgan Stanley
10/06/17
10/06/17
DOWNGRADE
Target $165

Equal Weight
Costco downgraded on EPS growth slowdown at Morgan Stanley
As previously reported, Morgan Stanley analyst Simeon Gutman downgraded Costco to Equal Weight from Overweight, stating that after its Q4 report last night he has cut his FY18 EPS growth estimate to $6.30. Moderating membership growth also led him to lower his EBITDA multiples, said Gutman, who added that the combination of decelerating EPS growth and "membership slippage" may make it tough for the stock to outperform. Gutman lowered his price target to $165 from $190 on Costco shares, which are down 4.5% to $159.50 in pre-market trading following last night's quarterly report.
10/06/17
RBCM
10/06/17
NO CHANGE
Target $190
RBCM
Outperform
Costco has some of the best traffic growth in retail, says RBC Capital
RBC Capital analyst Scot Ciccarelli said Costco reported better than expected Q4 results as total comps increased 5.7% versus his 5.3% estimate and consensus of 5.1%, while gross margin pressures were largely offset by expense leverage. Despite investors fears regarding risk from e-commerce, the analyst said Costco continues to have some of the best traffic growth in retail and is gaining traction from its own e-commerce initiates. Ciccarelli said he remains a buyer of Costo and increased his price target on shares to $190 from $184 and reiterated his Outperform rating on shares.
AMZN Amazon.com
$989.58

8.73 (0.89%)

10/06/17
RILY
10/06/17
NO CHANGE
Target $250
RILY
Buy
Amazon's Seller Flex expansion unlikely to impact Stamps.com, says B. Riley
B. Riley analyst Kevin Liu believes Amazon.com's (AMZN) plans to expand its Seller Flex program more broadly in 2018 following a two-year pilot in India and testing in West Coast states, as reported yesterday by Bloomberg, is unlikely to impact Stamps.com (STMP). The Seller Flex program Seller Flex arranges for the pickup and delivery of merchandise from the seller's distribution facility, which could potentially impact volumes currently routed through the major domestic carriers, Liu tells investors in a research note. He believes FedEx (FDX) and UPS (UPS) have the most to lose given their exposure to large shippers. The analyst sees "little risk at present" to Stamps.com given that Seller Flex is targets merchants with a "far greater" assortment, order volumes, and logistical footprint than is typically targeted by the company's various brands. Liu reiterates a Buy rating on Stamps.com with a $250 price target.
10/06/17
ROTH
10/06/17
NO CHANGE
Target $21
ROTH
Neutral
New CEO to tackle distribution concerns at Vista Outdoor, says Roth Capital
Roth Capital analyst Dave King says that despite the announcement of a new CEO hire by Vista Outdoor (VSTO), he still remains concerned about the "sustainability of Vista's distribution competitive advantage" and soft performance from recent acquisitions. King writes that incoming CEO Chris Metz brings extensive experience in driving operational improvements, as the company continues to focus on expanding its e-commerce presence and possibly grow its business with Amazon (AMZN). The analyst is also positive on the opportunity to capture market share in the ammo downturn, maintaining a Neutral rating and his $21 price target on Vista.
10/06/17
BARD
10/06/17
NO CHANGE
BARD
Amazon implications negative for FedEx, UPS, says Baird
Baird analyst Benjamin Hartford noted reports Amazon (AMZN) is testing its own final mile delivery service in the U.S. and he believes it is a logical extension of its model as it builds network density. The analyst believes the implications for parcel providers FedEx (FDX) and UPS (UPS) are negative, as it could put pressure on delivery rates and volume may be diverted from both. Hartford continues to rate FedEx with an Outperform and $235 price target and UPS remains Neutral rated with a $125 price target.
10/06/17
LEER
10/06/17
NO CHANGE
LEER
Leerink convinced Amazon entering drug distribution within two years
After calls with pharmacy benefit managers and retail pharmacy specialists, Leerink analyst Ana Gupte says she's convinced that Amazon.com (AMZN) "will almost certainly" enter the drug distribution value chain within two years, evolving into a more disruptive offering over time. Amazon's move is most threatening for retail pharmacies Walgreens Boots Alliance (WAB), CVS Health (CVS) and Wal-Mart (WMT), Gupte tells investors in a research note. The analyst calls Amazon both an opportunity and threat for Express Scripts (ESRX) and views UnitedHealth (UNH) and Humana (HUM) as "largely buffered." Gupte's conversations with specialists indicate Amazon is hiring relevant talent and is in active discussions with mid-market pharmacy benefit managers and possibly even with large players such as Prime Therapeutics. It is believed Amazon will start by capturing share in both the cash paying and third party mail order and possibly specialty pharmacy segments, Gupte notes. She expects Anthem (ANTM), Aetna (AET) and Cigna (CI) will likely to contemplate Amazon's entry in their upcoming PBM contract decisions.
SNCR Synchronoss
$14.15

3.43 (32.00%)

09/19/17
RAJA
09/19/17
DOWNGRADE
RAJA
Underperform
Synchronoss downgraded to Underperform from Outperform at Raymond James
Raymond James analyst Tavis McCourt downgraded Synchronoss (SNCR) two notches to Underperform from Outperform following news Siris Capital is no longer interested in an all-cash transaction for all the outstanding shares of the company and has withdrawn its $18 per share bid from June 22. Further, the analyst believes it increasingly unlikely that the current strategic review will result in an acquisition at a premium and expects share to come under pressure and stay in the range prior to the Siris indication of interest.
09/20/17
DBAB
09/20/17
NO CHANGE
Target $10
DBAB
Hold
Synchronoss price target lowered to $10 from $18 at Deutsche Bank
Deutsche Bank analyst Nandan Amladi cut his price target for Synchronoss Technologies to $10 citing increased uncertainty after Siris Capital decided not to pursue an all-cash acquisition of the company. Yesterday's 40% selloff retraces the pre-offer levels in June, Amladi tells investors in a research note. He continues to believe an eventual transaction "provides a clean exit" for Synchronoss shareholders, given the "mounting complications" facing the company. The analyst keeps a Hold rating on the shares.
06/22/17
JPMS
06/22/17
NO CHANGE
JPMS
Neutral
Synchronoss comments on carriers should help ease concerns, says JPMorgan
JPMorgan analyst Sterling Auty said that comments made by Synchronoss (SNCR) in a presentation to its lenders regarding AT&T (T) and Verizon (VZ) continuing to be cloud customers should help ease some of the concern investors have had around the company's cloud business. Auty keeps a Neutral rating on Synchronoss shares.
09/19/17
09/19/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Underperform from Market Perform at Wells Fargo with Wells Fargo with analyst Tom Nikic saying with consumers having filled their closets with athletic wear over the past seven years, the category "appears poised to take a breather for now." The analyst cut his price target for the shares to $13 from $17. 2. Kellogg (K) downgraded to Neutral from Overweight at Piper Jaffray with analyst Michael Lavery saying cereal could be at risk from shrinking center store space. 3. Nike (NKE) downgraded to Neutral from Positive at Susquehanna saying that his checks indicate that the North American and European businesses are decelerating as some key categories, especially basketball, have underperformed, resulting in excess inventory that will pressure sales and margins. 4. Synchronoss (SNCR) downgraded to Underperform from Outperform at Raymond James with analyst Tavis McCourt citing the news that Siris Capital is no longer interested in an all-cash transaction for all the outstanding shares of the company and has withdrawn its $18 per share bid from June 22. Further, the analyst believes it increasingly unlikely that the current strategic review will result in an acquisition at a premium and expects share to come under pressure and stay in the range prior to the Siris indication of interest. 5. Sony (SNE) downgraded to Neutral from Outperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GSM Ferroglobe
$14.76

1.24 (9.17%)

10/06/17
OPCO
10/06/17
NO CHANGE
Target $18
OPCO
Outperform
Anti-dumping ruling highly favorable for Ferroglobe, says Oppenheimer
Oppenheimer analyst Ian Zaffino views the Department of Commerce's preliminary anti-dumping duties against Australia, Brazil and Norway for silicon metal as highly favorable for Ferroglobe. The largest importer of silicon metal, Brazi, was hit with the highest rate of 56.78%-134.92%, the analyst notes. The duties should put "meaningful upward pressure" on silicon metal prices, which currently stand at $1.24 versus $1.46 in January 2015, Zaffino tells investors in a research note. He reminds investors that 10c per pound move in silicon metal represents an incremental $70M in EBITDA for Ferroglobe. The analyst maintains an Outperform rating on the shares with an $18 price target.
11/15/16
JPMS
11/15/16
DOWNGRADE
Target $10
JPMS
Neutral
Ferroglobe downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Gambardella downgraded Ferroglobe to Neutral saying the company's volumes for silicon metals, silicon alloys, and manganese alloys have all been sliding lower throughout the year. The analyst lowered his price target for the shares to $10 from $12.
08/18/17
JEFF
08/18/17
NO CHANGE
Target $17
JEFF
Buy
Ferroglobe price target raised to $17 from $12 at Jefferies
Jefferies analyst Martin Englert raised his price target for Ferroglobe to $17 and reiterates a Buy rating on the shares. There is a "confluence of positive indicators pointing to a possible perfect storm" driving silicon metal prices incrementally higher, Englert tells investors in a research note. The analyst raised his EBITDA estimates for Ferroglobe by 40% for 2017-2018, largely on higher pricing.
03/13/17
RILY
03/13/17
INITIATION
Target $14.25
RILY
Buy
Ferroglobe resumed with a Buy at B. Riley
B. Riley analyst Ian Corydon resumed coverage of Ferroglobe with a Buy rating and $14.25 price target.
ALB Albemarle
$137.19

-2.47 (-1.77%)

10/06/17
GSCO
10/06/17
DOWNGRADE
GSCO
Neutral
Albemarle downgraded to Neutral from Conviction Buy at Goldman Sachs
Goldman Sachs analyst Robert Koort downgraded Albemarle to Neutral and removed the shares from his firm's Conviction Buy list. The company over the past two years has transformed from a value-oriented chemical stock into a "thematic growth engine" as investors shifted their focus to the potential of an electric vehicle revolution, Koort tells investors in a research note. The analyst believes the upside is priced in with the stock close to his unchanged price target for $142. He believes, however, that the lithium market will remain tight through the end of the decade. Albemarle closed yesterday up $1.44 to $139.66.
09/29/17
LOOP
09/29/17
INITIATION
LOOP
Buy
Albemarle initiated at Loop Capital
As noted earlier, Loop Capital started coverage of Albemarle with a $150 price target and a Buy rating. Analyst Chris Kapsch calls the company " arguably the best organic growth story across the chemicals/materials space" and a "must-own " stock. The analyst expects the stock to rise further, given the rapid expected growth of the electric car market.
09/28/17
LOOP
09/28/17
INITIATION
LOOP
Buy
Albemarle initiated with a Buy at Loop Capital
Loop Capital analyst Chris Kapsch initiated Albemarle with a Buy rating and $150 price target.
10/06/17
10/06/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Spirit Airlines (SAVE) downgraded to Hold from Buy at Deutsche Bank with analyst Michael Linenberg saying the company's revenue outlook "may face greater downside risk" than peers given the competitive intensity of its markets. 2. Albemarle (ALB) downgraded to Neutral from Conviction Buy at Goldman Sachs with analyst Robert Koort saying the company over the past two years has transformed from a value-oriented chemical stock into a "thematic growth engine" as investors shifted their focus to the potential of an electric vehicle revolution. 3. Cree (CREE) downgraded to Underweight from Neutral at JPMorgan with analyst Paul Coster citing valuation. 4. Valero (VLO) downgraded to Neutral from Overweight at JPMorgan with Phil Gresh citing valuation following the recent rally. 5. Walgreens Boots Alliance (WBA) downgraded to Equal Weight at Morgan Stanley with analyst Ricky Goldwasser saying he expects the company's guidance to come in below consensus estimates when it is provided later this month. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
DAR Darling Ingredients
$16.38

-1.51 (-8.44%)

08/14/17
JPMS
08/14/17
NO CHANGE
Target $19
JPMS
Overweight
Darling Ingredients price target raised to $19 from $17 at JPMorgan
JPMorgan analyst Thomas Palmer raised his price target for Darling Ingredients to $19 following last week's Q2 results. The company's Diamond Green Diesel joint venture is beginning to demonstrate the long-term earnings ramp management has long spoke about, Palmer tells investors in a research note. The analyst reiterates an Overweight rating on the shares.
03/22/17
BARD
03/22/17
INITIATION
Target $19
BARD
Outperform
Darling Ingredients initiated with an Outperform at Baird
Baird analyst Ben Kallo initiated Darling with an Outperform and a $19 price target.
09/26/17
BARD
09/26/17
NO CHANGE
Target $20
BARD
Outperform
Darling Ingredients remains a top pick, says Baird
Baird analyst Ben Kallo said key drivers are in place to support substantial EBITDA growth in 2018 and beyond for Darling Ingredients. The analyst also cited key regulatory drivers as well and said others could fall into place, which will boost the company's growth profile. Kallo reiterated his Outperform rating and $20 price target on Darling Ingredients and said it remains a top pick.
10/06/17
JPMS
10/06/17
DOWNGRADE
Target $18
JPMS
Neutral
Darling Ingredients downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Thomas Palmer downgraded Darling Ingredients to Neutral citing valuation with the shares up 39% year-to-date as well as regulatory risk. The U.S. Commerce Department's preliminary duties on biodiesel imports from Argentina and Indonesia were greater than anticipated and the EPA's decision to potentially reduce biomass-based diesel mandates for 2018 and 2019 could also weigh on pricing, Palmer tells investors in a research note. The analyst lowered his price atrget for the shares to $18 from $19.

TODAY'S FREE FLY STORIES

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

, ABBV

AbbVie

$118.60

3.7 (3.22%)

04:55
02/18/18
02/18
04:55
02/18/18
04:55
Conference/Events
American Academy of Dermatology holds annual meeting »

2018 AAD Annual Meeting…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

AGN

Allergan

$164.04

-0.43 (-0.26%)

ALIOF

Actelion

ARDX

Ardelyx

$5.80

-0.2 (-3.33%)

BVX

Bovie Medical

$2.50

0.1 (4.17%)

CELG

Celgene

$95.26

-0.88 (-0.92%)

CUTR

Cutera

$48.40

-2.1 (-4.16%)

HSIC

Henry Schein

$69.52

1.14 (1.67%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

LLY

Eli Lilly

$78.97

0.95 (1.22%)

LMNS

Lumenis

MYGN

Myriad Genetics

$32.81

-0.57 (-1.71%)

MYL

Mylan

$42.14

0.49 (1.18%)

NVS

Novartis

$86.91

0.23 (0.27%)

PFE

Pfizer

$36.26

0.55 (1.54%)

PG

Procter & Gamble

$82.60

0.19 (0.23%)

PRGO

Perrigo

$89.55

-0.1 (-0.11%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNY

Sanofi

$39.91

0.19 (0.48%)

UL

Unilever; also tag UN

$53.55

-0.22 (-0.41%)

UN

Unilever; also tag UL

$54.59

-0.15 (-0.27%)

WTKWY

Wolters Kluwer

$49.37

-0.27 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 02

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 12

    Mar

  • 12

    Mar

  • 25

    Mar

  • 29

    Mar

  • 04

    Apr

  • 23

    Apr

  • 23

    Apr

  • 02

    May

  • 03

    May

  • 17

    May

  • 30

    May

  • 13

    Nov

MRVL

Marvell

$22.68

-0.06 (-0.26%)

, CAVM

Cavium

$87.16

-0.09 (-0.10%)

14:55
02/17/18
02/17
14:55
02/17/18
14:55
Conference/Events
Cavium to host special shareholder meeting »

Special Shareholder…

MRVL

Marvell

$22.68

-0.06 (-0.26%)

CAVM

Cavium

$87.16

-0.09 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 08

    Mar

CAVM

Cavium

$87.16

-0.09 (-0.10%)

, MRVL

Marvell

$22.68

-0.06 (-0.26%)

14:51
02/17/18
02/17
14:51
02/17/18
14:51
Conference/Events
Marvell to host special shareholder meeting »

Special Shareholder…

CAVM

Cavium

$87.16

-0.09 (-0.10%)

MRVL

Marvell

$22.68

-0.06 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

DEL

Deltic Timber

$98.45

1.77 (1.83%)

, PCH

Potlatch

$54.75

0.75 (1.39%)

14:45
02/17/18
02/17
14:45
02/17/18
14:45
Conference/Events
Potlatch to host special shareholder meeting »

Special Shareholder…

DEL

Deltic Timber

$98.45

1.77 (1.83%)

PCH

Potlatch

$54.75

0.75 (1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

PCH

Potlatch

$54.75

0.75 (1.39%)

, DEL

Deltic Timber

$98.45

1.77 (1.83%)

14:42
02/17/18
02/17
14:42
02/17/18
14:42
Conference/Events
Deltic Timber to host special shareholder meeting »

Special shareholder…

PCH

Potlatch

$54.75

0.75 (1.39%)

DEL

Deltic Timber

$98.45

1.77 (1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$20.42

0.67 (3.39%)

09:31
02/17/18
02/17
09:31
02/17/18
09:31
Periodicals
Snap CEO sold $50M in stock this week, Recode reports »

Snap CEO Evan Spiegel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 07

    Mar

GLPG

Galapagos NV

$115.33

-1.4 (-1.20%)

, MPSYY

MorphoSys

$46.29

1.29 (2.87%)

09:27
02/17/18
02/17
09:27
02/17/18
09:27
Hot Stocks
Galapagos NV, MorphoSys present results from Phase 1 study with MOR106 in AD »

Galapagos NV (GLPG) and…

GLPG

Galapagos NV

$115.33

-1.4 (-1.20%)

MPSYY

MorphoSys

$46.29

1.29 (2.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$360.53

-0.47 (-0.13%)

09:22
02/17/18
02/17
09:22
02/17/18
09:22
Hot Stocks
Lockheed Martin receives Freedom-variant FFG conceptual design contract »

The U.S. Navy awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 07

    Mar

  • 30

    May

UAA

Under Armour; also tag UA

$17.36

-1.05 (-5.70%)

, UA

Under Armour; also tag UAA

$15.78

-0.76 (-4.59%)

09:11
02/17/18
02/17
09:11
02/17/18
09:11
Periodicals
Bears, bulls battle over Under Armour, Barron's says »

In a follow-up story,…

UAA

Under Armour; also tag UA

$17.36

-1.05 (-5.70%)

UA

Under Armour; also tag UAA

$15.78

-0.76 (-4.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOV

Hovnanian

$2.24

0.12 (5.66%)

09:04
02/17/18
02/17
09:04
02/17/18
09:04
Periodicals
Hovnanian stock too cheap to ignore, Barron's says »

Hovnanian Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

, JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

09:00
02/17/18
02/17
09:00
02/17/18
09:00
Periodicals
JPMorgan, Walmart cash flow yields exceed dividend yields, Barron's says »

The cash flow yields of…

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

WMT

Walmart

$104.78

1.55 (1.50%)

PFE

Pfizer

$36.26

0.55 (1.54%)

CSCO

Cisco

$44.33

0.25 (0.57%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

PEP

PepsiCo

$111.06

0.09 (0.08%)

MMM

3M

$236.67

1.8 (0.77%)

BMY

Bristol-Myers

$68.96

-0.02 (-0.03%)

UTX

United Technologies

$129.26

-0.74 (-0.57%)

TXN

Texas Instruments

$104.47

-0.1 (-0.10%)

ABT

Abbott

$60.17

0.67 (1.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Feb

  • 19

    Feb

  • 20

    Feb

  • 21

    Feb

  • 23

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 13

    Mar

  • 29

    Mar

  • 04

    Apr

  • 13

    Apr

  • 30

    May

  • 14

    Jul

  • 12

    Oct

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

, GOOG

Alphabet

$1,094.80

5.28 (0.48%)

08:56
02/17/18
02/17
08:56
02/17/18
08:56
Periodicals
Alphabet, Citi well positioned for later stages of market rally, Barron's says »

It is time for investors…

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

GOOG

Alphabet

$1,094.80

5.28 (0.48%)

C

Citi

$76.82

-0.26 (-0.34%)

CMI

Cummins

$165.60

0.58 (0.35%)

LRCX

Lam Research

$187.91

2.2 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 18

    Mar

  • 28

    Mar

  • 29

    Mar

  • 30

    May

GE

General Electric

$15.05

0.2 (1.35%)

08:48
02/17/18
02/17
08:48
02/17/18
08:48
Periodicals
General Electric stock could drop another 10%, Barron's says »

General Electric lost $6B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$63.19

-0.52 (-0.82%)

, VMC

Vulcan Materials

$126.57

-6.9 (-5.17%)

08:32
02/17/18
02/17
08:32
02/17/18
08:32
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

JEC

Jacobs Engineering

$63.19

-0.52 (-0.82%)

VMC

Vulcan Materials

$126.57

-6.9 (-5.17%)

PWR

Quanta Services

$35.07

0.24 (0.69%)

EXP

Eagle Materials

$102.75

-3.83 (-3.59%)

FLR

Fluor

$57.63

-0.22 (-0.38%)

USCR

U.S. Concrete

$78.00

-1.4 (-1.76%)

ACM

Aecom

$35.36

0.08 (0.23%)

CBI

CB&I

$18.71

0.04 (0.21%)

GVA

Granite Construction

$60.36

2.69 (4.66%)

CAT

Caterpillar

$156.29

-3.69 (-2.31%)

MLM

Martin Marietta

$216.25

-6.34 (-2.85%)

V

Visa

$121.85

-0.43 (-0.35%)

AA

Alcoa

$47.36

-0.21 (-0.44%)

ARNC

Arconic

$25.36

0.14 (0.56%)

CENX

Century Aluminum

$24.12

1.85 (8.31%)

X

U.S. Steel

$44.75

5.76 (14.77%)

STLD

Steel Dynamics

$49.40

2.26 (4.79%)

AKS

AK Steel

$5.96

0.72 (13.74%)

CLF

Cleveland-Cliffs

$7.92

0.55 (7.46%)

NUE

Nucor

$68.54

2.96 (4.51%)

MT

ArcelorMittal

$36.48

1.19 (3.37%)

TKR

Timken

$45.00

-0.08 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 01

    Mar

  • 14

    Mar

  • 23

    May

  • 30

    May

04:55
02/17/18
02/17
04:55
02/17/18
04:55
Conference/Events
Cambridge Healthtech Institute to hold a conference »

Molecular Med Tri-Con…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

, ABBV

AbbVie

$118.60

3.7 (3.22%)

04:55
02/17/18
02/17
04:55
02/17/18
04:55
Conference/Events
American Academy of Dermatology holds annual meeting »

2018 AAD Annual Meeting…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

AGN

Allergan

$164.04

-0.43 (-0.26%)

ALIOF

Actelion

ARDX

Ardelyx

$5.80

-0.2 (-3.33%)

BVX

Bovie Medical

$2.50

0.1 (4.17%)

CELG

Celgene

$95.26

-0.88 (-0.92%)

CUTR

Cutera

$48.40

-2.1 (-4.16%)

HSIC

Henry Schein

$69.52

1.14 (1.67%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

LLY

Eli Lilly

$78.97

0.95 (1.22%)

LMNS

Lumenis

MYGN

Myriad Genetics

$32.81

-0.57 (-1.71%)

MYL

Mylan

$42.14

0.49 (1.18%)

NVS

Novartis

$86.91

0.23 (0.27%)

PFE

Pfizer

$36.26

0.55 (1.54%)

PG

Procter & Gamble

$82.60

0.19 (0.23%)

PRGO

Perrigo

$89.55

-0.1 (-0.11%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNY

Sanofi

$39.91

0.19 (0.48%)

UL

Unilever; also tag UN

$53.55

-0.22 (-0.41%)

UN

Unilever; also tag UL

$54.59

-0.15 (-0.27%)

WTKWY

Wolters Kluwer

$49.37

-0.27 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 02

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 12

    Mar

  • 12

    Mar

  • 25

    Mar

  • 29

    Mar

  • 04

    Apr

  • 23

    Apr

  • 02

    May

  • 03

    May

  • 17

    May

  • 30

    May

  • 13

    Nov

MIDD

Middleby

$135.00

1.94 (1.46%)

18:01
02/16/18
02/16
18:01
02/16/18
18:01
Hot Stocks
Middleby acquires Hinds-Bock Corporation, terms not disclosed »

Middleby announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.14

0.14 (0.38%)

, TWX

Time Warner

$95.37

0.38 (0.40%)

17:37
02/16/18
02/16
17:37
02/16/18
17:37
Periodicals
Breaking Periodicals news story on AT&T, Time Warner »

Judge says to rule on …

T

AT&T

$37.14

0.14 (0.38%)

TWX

Time Warner

$95.37

0.38 (0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 23

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 05

    Mar

CARS

Cars.com

$29.27

0.33 (1.14%)

17:31
02/16/18
02/16
17:31
02/16/18
17:31
Hot Stocks
Breaking Hot Stocks news story on Cars.com »

Starboard raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONTX

Onconova

$1.07

0.01 (0.94%)

17:29
02/16/18
02/16
17:29
02/16/18
17:29
Hot Stocks
683 Capital reports 21.8% stake in Onconova, says shares undervalued »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$224.19

-1.21 (-0.54%)

17:26
02/16/18
02/16
17:26
02/16/18
17:26
Hot Stocks
General Dynamics awarded $148.9M government contract modification »

General Dynamics Land…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRS

Antares Pharma

$2.39

0.04 (1.70%)

17:25
02/16/18
02/16
17:25
02/16/18
17:25
Hot Stocks
Breaking Hot Stocks news story on Antares Pharma »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HII

Huntington Ingalls

$265.70

10.31 (4.04%)

17:25
02/16/18
02/16
17:25
02/16/18
17:25
Hot Stocks
Huntington Ingalls awarded $1.43B government contract modification »

Huntington Ingalls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

DIT

AMCON Distributing

$87.50

0.13 (0.15%)

17:24
02/16/18
02/16
17:24
02/16/18
17:24
Hot Stocks
Breaking Hot Stocks news story on AMCON Distributing »

Hale Partnership reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$41.09

-0.76 (-1.82%)

, TSLA

Tesla

$335.49

1.425 (0.43%)

17:11
02/16/18
02/16
17:11
02/16/18
17:11
Periodicals
Chevy Bolt sales bolstered by Tesla delays, tax credit worries, Reuters says »

Certain potential buyers…

GM

General Motors

$41.09

-0.76 (-1.82%)

TSLA

Tesla

$335.49

1.425 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.